Colistimethate 1MU InjectionInjection
Antibiotics

Colistimethate 1MU Injection

Colistimethate Sodium

Polymyxin antibiotic reserved as last-resort treatment for MDR gram-negative infections including carbapenem-resistant organisms. Manufactured by Cipla and Glenmark for ICU export.

Strengths

1 MU / 2 MU

Packing

1 vial/box

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Colistimethate Sodium 1 Million Units (MU) lyophilized powder
Dosage Form
Injection
Available Strengths
1 MU / 2 MU
Packing
1 vial/box
Route of Administration
Intravenous infusion or nebulization
Dosage
2.5-5mg/kg/day CBA IV in 2-3 divided doses; adjust for renal function; loading dose recommended
Indications
MDR gram-negative infections including carbapenem-resistant Acinetobacter and Pseudomonas, ventilator-associated pneumonia
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 25°C
Shelf Life
36 months
Side Effects
Nephrotoxicity, neurotoxicity, paresthesias, bronchospasm (inhaled), dizziness
Precautions
Nephrotoxicity is dose-limiting; monitor renal function closely; avoid with other nephrotoxic agents; neurotoxicity risk; TDM recommended

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Azithromycin 500mgTablet

Azithromycin 500mg

Azithromycin

Azalide subclass macrolide antibiotic that achieves exceptionally high and sustained intracellular tissue concentrations — up to 100-fold higher than plasma levels — enabling short 3-day or 5-day treatment courses for respiratory, skin, and sexually transmitted bacterial infections. Its anti-inflammatory properties beyond direct bacteriostasis provide additional clinical benefit in community-acquired pneumonia. Cipla and Alkem Labs manufacture 250mg and 500mg tablets exported globally as a staple of primary care antibiotic formularies.

250mg / 500mg
Amoxicillin 500mgCapsule

Amoxicillin 500mg

Amoxicillin Trihydrate

Aminopenicillin with extended gram-positive and gram-negative bactericidal activity, offering superior oral bioavailability (~90%) compared to ampicillin and the convenience of twice- or thrice-daily dosing for common community infections of the respiratory tract, urinary tract, skin, and ear. It is also a key component of H. pylori triple-eradication therapy and is a WHO Essential Medicine available in both capsule and dispersible tablet forms. Cipla and GSK manufacture 250mg and 500mg capsules exported to primary care markets globally.

250mg / 500mg
Augmentin 625mgTablet

Augmentin 625mg

Amoxicillin + Clavulanate

Fixed-dose combination of amoxicillin with clavulanic acid, a potent beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation and restores its activity against beta-lactamase-producing strains of Staphylococcus, Haemophilus, Moraxella, and Klebsiella commonly encountered in community and hospital settings. Widely prescribed for sinusitis, otitis media, lower respiratory infections, UTIs, animal bites, and dental abscesses resistant to amoxicillin alone. GSK and Cipla supply 625mg and 1g tablets exported as a primary care antibiotic staple worldwide.

625mg / 1g

Need bulk pricing for Colistimethate 1MU Injection?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote